Nebulized Budesonide for Children Who Are Hospitalized for Acute Wheezing

• Status: Completed
• Trial end date: 2010-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine if adding nebulized budesonide to the systemic steroid for treatment of acute wheezing has any additive benefit in children who have hospitalized for acute wheezing.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kecioren Education and Training Hospital
• Treatments: Budesonide

Criteria

Inclusion Criteria:

• Children who have recurrent wheezing attacks

• Children who admitted to the hospital for acute wheezing

• Clinical asthma score of 3-9

• Parental/guardian permission (informed consent) and if appropriate, child assent

Exclusion Criteria:

• Systemic corticosteroid use in the last 30 days

• Chronic lung diseases including cystic fibrosis

• Immunodeficiency

• Cardiac disease requiring surgery or medications

• Adverse drug reaction or allergy to budesonide, albuterol, ipratropium bromide, prednisone, prednisolone, or methylprednisolone

• Known renal or hepatic dysfunction

• Impending respiratory failure requiring positive pressure ventilation

• Immune deficiency

• Gastroesophageal reflux disease

• Suspected foreign body aspiration or croup

• Anatomic abnormalities of the respiratory tract